Fulcrum Therapeutics Company Insiders
FULC Stock | USD 7.65 0.29 3.65% |
Fulcrum Therapeutics employs about 45 people. The company is managed by 16 executives with a total tenure of roughly 105 years, averaging almost 6.0 years of service per executive, having 2.81 employees per reported executive. Evaluation of Fulcrum Therapeutics' management performance can provide insight into the firm performance.
Fulcrum Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0274) % which means that it has lost $0.0274 on every $100 spent on assets. This is way below average. Fulcrum Therapeutics' management efficiency ratios could be used to measure how well Fulcrum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Fulcrum Therapeutics Workforce Comparison
Fulcrum Therapeutics is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,041. Fulcrum Therapeutics holds roughly 45.0 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13. Fulcrum Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulcrum Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulcrum Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Fulcrum Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ezekowitz Alan over three weeks ago Acquisition by Ezekowitz Alan of 36000 shares of Fulcrum Therapeutics at 7.38 subject to Rule 16b-3 | ||
Tourangeau Greg over two months ago Disposition of 498 shares by Tourangeau Greg of Fulcrum Therapeutics at 5.06 subject to Rule 16b-3 | ||
Haviland Kate over three months ago Acquisition by Haviland Kate of 19000 shares of Fulcrum Therapeutics at 5.22 subject to Rule 16b-3 | ||
Mel Hayes over three months ago Acquisition by Mel Hayes of 137000 shares of Fulcrum Therapeutics subject to Rule 16b-3 | ||
Tourangeau Greg over three months ago Disposition of 3410 shares by Tourangeau Greg of Fulcrum Therapeutics at 16.87 subject to Rule 16b-3 | ||
Oltmans Curtis Gale over three months ago Acquisition by Oltmans Curtis Gale of 225000 shares of Fulcrum Therapeutics at 4.16 subject to Rule 16b-3 | ||
Gould Robert J over six months ago Disposition of 6766 shares by Gould Robert J of Fulcrum Therapeutics at 15.0 subject to Rule 16b-3 | ||
King Rachel K. over six months ago Insider Trading |
Fulcrum Therapeutics Notable Stakeholders
A Fulcrum Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Fulcrum Therapeutics often face trade-offs trying to please all of them. Fulcrum Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Fulcrum Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Green | Co-Founder | Profile | |
TsunHuei MD | Founder | Profile | |
Alexander Sapir | President CEO | Profile | |
Curtis JD | Chief VP | Profile | |
Rudolf MD | Founder | Profile | |
CPA CMA | Chief Officer | Profile | |
Jeffrey Jacobs | Chief Officer | Profile | |
Mel Hayes | Executive Experience | Profile | |
Paul Bruno | Senior Development | Profile | |
Bryan Stuart | CEO Pres | Profile | |
Esther Rajavelu | CFO Treasurer | Profile | |
Gregory Tourangeau | Controller Officer | Profile | |
Kim Hazen | Chief Officer | Profile | |
Prof MD | Founder | Profile | |
Danny Reinberg | Founder | Profile | |
Judith Dunn | Interim Officer | Profile |
About Fulcrum Therapeutics Management Performance
The success or failure of an entity such as Fulcrum Therapeutics often depends on how effective the management is. Fulcrum Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Fulcrum management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Fulcrum management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.
Please note, the presentation of Fulcrum Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fulcrum Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fulcrum Therapeutics' management manipulating its earnings.
Fulcrum Therapeutics Workforce Analysis
Traditionally, organizations such as Fulcrum Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Fulcrum Therapeutics within its industry.Fulcrum Therapeutics Manpower Efficiency
Return on Fulcrum Therapeutics Manpower
Revenue Per Employee | 1.8M | |
Revenue Per Executive | 5M | |
Net Loss Per Employee | 216.1K | |
Net Loss Per Executive | 607.8K | |
Working Capital Per Employee | 5.3M | |
Working Capital Per Executive | 14.9M |
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |